Please login to the form below

Not currently logged in

progressive supranuclear palsy

This page shows the latest progressive supranuclear palsy news and features for those working in and with pharma, biotech and healthcare.

Roche pays $120m upfront for UCB’s anti-tau Alzheimer’s drug

Roche pays $120m upfront for UCB’s anti-tau Alzheimer’s drug

The investigational treatment, UCB0107, is a monoclonal antibody drug being developed by UCB as a potential treatment for patients with tauopathies, such as progressive supranuclear palsy (PSP) and Alzheimer’s disease. ... Tau pathology is indicated in

Latest news

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...